STOK Clinical trials

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Published August 11, 2025 at 11:00 AM

BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Zorevunersen, an investigational antisense oligonucleotide, has the potential to be the first disease-modifyi

Related Questions

How will the first patient dosing in the Phase 3 EMPEROR study affect Stoke Therapeutics’ (STOK) stock price in the short‑term and over the next 12‑24 months? What are the key milestones and expected timelines for data read‑outs (interim and final) from the EMPEROR trial, and how might those dates influence market movements? What is the size of the addressable market for Dravet syndrome therapies and how does the potential market for a disease‑modifying treatment compare to existing symptomatic treatments? What is the expected regulatory pathway (e.g., FDA Fast Track, Orphan Drug, and potential accelerated approval) for zorevunersen, and what impact could that have on valuation? How does zorevunersen’s mechanism of action (antisense oligonucleotide for SCN1A) compare to other pipelines (e.g., gene‑therapy or small‑molecule approaches) being pursued by competitors such as Novartis, Roche, and GeneTX? What is the financial exposure for Stoke Therapeutics versus Biogen in the EMPEROR trial (cost sharing, milestone payments, royalties) and how could that affect each company’s balance sheet? What are the potential risks (clinical, regulatory, safety) that could cause the trial to fail or be delayed, and how should those risks be priced into the stock? What is the expected pricing and reimbursement outlook for a disease‑modifying therapy for Dravet syndrome, and how might that affect future revenue projections for both companies? How will the partnership with Biogen impact Stoke’s future partnership strategy and potential dilution of existing shareholders? What is the likely impact on Biogen’s overall pipeline and earnings guidance from the addition of a potential first‑in‑class disease‑modifying therapy for a rare epileptic disorder?